The Benefits of Physical Activity for Patients with Cystic Fibrosis: A Literature Review
DOI:
https://doi.org/10.12775/QS.2024.18.53457Keywords
Cystic fibrosis, Exercise, Physical activityAbstract
Introduction
Cystic fibrosis (CF) is a complex and progressive genetic disorder that significantly impacts multiple organ systems, particularly the lungs and digestive tract. Despite advances in treatment and improved life expectancy, CF remains incurable, necessitating ongoing research and comprehensive management strategies. One of the key components in managing CF is the incorporation of physical activity (PA).
Aim of the study
The aim of the study is to investigate the role of physical activity in in the management of cystic fibrosis.
Materials and methods
This study underscores the critical role of physical activity (PA) in the management and overall well-being of individuals with cystic fibrosis (CF). It provides a comprehensive review of the multifaceted benefits of PA for CF patients, highlighting its positive impact on exercise tolerance, pulmonary function, cardiorespiratory fitness, muscle strength, and quality of life. PubMed and Google Scholar database was searched for articles written in English. The search included the keywords.
Results
The data suggest that while CF patients face unique challenges, including muscle weakness and exercise intolerance, regular PA can mitigate these effects and improve overall health outcomes. Supervised exercise programs have demonstrated significant improvements in exercise tolerance and respiratory muscle endurance without adverse effects, indicating their feasibility and safety for CF patients. Studies have shown that patients with CF who engage in regular PA experience slower declines in lung function, fewer hospitalizations, and better nutritional status. Specific types of exercise, such as anaerobic training, have been particularly effective in increasing muscle strength and body weight.
References
Myer H, Chupita S, Jnah A. Cystic Fibrosis: Back to the Basics. Neonatal Netw 2023;42:23–30. https://doi.org/10.1891/NN-2022-0007.
Nicklas TA, Webber LS, Johnson CC, Srinivasan SR, Berenson GS. Foundations for health promotion with youth: A review of observations from the bogalusa heart study. J Health Educ 1995;26:S18–26. https://doi.org/10.1080/10556699.1995.10603142.
Di Lullo AM, Iacotucci P, Comegna M, Amato F, Dolce P, Castaldo G, et al. Cystic Fibrosis: The Sense of Smell. Am J Rhinol Allergy 2020;34:35–42. https://doi.org/10.1177/1945892419870450.
Schneider-Futschik EK. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis. Gene Ther 2019;26:354–62. https://doi.org/10.1038/S41434-019-0092-5.
Cystic Fibrosis Foundation n.d. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf (accessed July 12, 2024).
Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008;32:783–95. https://doi.org/10.1183/09031936.00146807.
Davis PB. Cystic Fibrosis Since 1938. Https://DoiOrg/101164/Rccm200505-840OE 2012;173:475–82. https://doi.org/10.1164/RCCM.200505-840OE.
Houwen RH, Van Der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr 2010;50:38–42. https://doi.org/10.1097/MPG.0B013E3181A6E01D.
Moore JE, Mastoridis P. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis. J Clin Pharm Ther 2017;42:259–67. https://doi.org/10.1111/JCPT.12521.
Terlizzi V, Castaldo G, Salvatore D, Lucarelli M, Raia V, Angioni A, et al. Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. J Med Genet 2017;54:224–35. https://doi.org/10.1136/JMEDGENET-2016-103985.
Widerman E. Knowledge, interests and educational needs of adults diagnosed with Cystic Fibrosis after age 18. Journal of Cystic Fibrosis 2003;2:97–104. https://doi.org/10.1016/S1569-1993(03)00026-2.
Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: A 2002 update. J Pediatr 2002;140:156–64. https://doi.org/10.1067/MPD.2002.120269.
Antunovic SS, Lukac M, Vujovic D. Longitudinal cystic fibrosis care. Clin Pharmacol Ther 2013;93:86–97. https://doi.org/10.1038/CLPT.2012.183.
Abeliovich D, Lavon IP, Lerer I, Cohen T, Springer C, Avital A, et al. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet 1992;51:951.
Lukacs GL, Durie PR. Pharmacologic approaches to correcting the basic defect in cystic fibrosis. N Engl J Med 2003;349:1401–4. https://doi.org/10.1056/NEJMP038113.
Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011;183:1463–71. https://doi.org/10.1164/RCCM.201009-1478CI.
Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19:10–5. https://doi.org/10.1002/PPUL.1950190103.
Milla CE, Moss RB. Recent advances in cystic fibrosis. Curr Opin Pediatr 2015;27:317–24. https://doi.org/10.1097/MOP.0000000000000226.
Stephenson AL, Stanojevic S, Sykes J, Burgel PR. The changing epidemiology and demography of cystic fibrosis. Presse Med 2017;46:e87–95. https://doi.org/10.1016/J.LPM.2017.04.012.
Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020;8:65–124. https://doi.org/10.1016/S2213-2600(19)30337-6.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663–72. https://doi.org/10.1056/NEJMOA1105185.
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 2015;373:220–31. https://doi.org/10.1056/NEJMOA1409547.
Kalamara EI, Ballas ET, Pitsiou G, Petrova G. Pulmonary rehabilitation for cystic fibrosis: A narrative review of current literature. Monaldi Arch Chest Dis 2021;91. https://doi.org/10.4081/MONALDI.2021.1501.
Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: A 2002 update. Journal of Pediatrics 2002;140:156–64. https://doi.org/10.1067/mpd.2002.120269.
Laborde-Castérot H, Donnay C, Chapron J, Burgel PR, Kanaan R, Honoré I, et al. Employment and work disability in adults with cystic fibrosis. Journal of Cystic Fibrosis 2012;11:137–43. https://doi.org/10.1016/J.JCF.2011.10.008.
Swisher AK, Alway SE, Yeater R. The effect of exercise on peripheral muscle in emphysema: A preliminary investigation. COPD: Journal of Chronic Obstructive Pulmonary Disease 2006;3:9–15. https://doi.org/10.1080/15412550500493287/ASSET/A1D49AFD-1C33-4898-9FA6-F1E99A7270A9/ASSETS/IMAGES/ICOP_A_149311_UF0001_B.GIF.
Painter P. Exercise in chronic disease: Physiological research needed. Exerc Sport Sci Rev 2008;36:83–90. https://doi.org/10.1097/JES.0B013E318168EDEF.
Nixon PA, Orenstein DM, Kelsey SF. Habitual physical activity in children and adolescents with cystic fibrosis. Med Sci Sports Exerc 2001;33:30–5. https://doi.org/10.1097/00005768-200101000-00006.
Boucher GP, Lands LC, Hay JA, Hornby L. Activity levels and the relationship to lung function and nutritional status in children with cystic fibrosis. Am J Phys Med Rehabil 1997;76:311–5. https://doi.org/10.1097/00002060-199707000-00010.
Burtin C, Hebestreit H. Rehabilitation in patients with chronic respiratory disease other than chronic obstructive pulmonary disease: exercise and physical activity interventions in cystic fibrosis and non-cystic fibrosis bronchiectasis. Respiration 2015;89:181–9. https://doi.org/10.1159/000375170.
Kinaupenne M, De Craemer M, Schaballie H, Vandekerckhove K, Van Biervliet S, Demeyer H. Physical activity and its correlates in people with cystic fibrosis: a systematic review. European Respiratory Review 2022;31. https://doi.org/10.1183/16000617.0010-2022.
Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992;327:1785–8. https://doi.org/10.1056/NEJM199212173272504.
Hillsdon M, Foster C, Thorogood M. Interventions for promoting physical activity (Review) 2006.
Hebestreit H, Kriemler S, Radtke T. Exercise for all cystic fibrosis patients: Is the evidence strengthening? Curr Opin Pulm Med 2015;21:591–5. https://doi.org/10.1097/MCP.0000000000000214.
Savi D, Schiavetto S, Simmonds NJ, Righelli D, Palange P. Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis. Journal of Cystic Fibrosis 2019;18:420–4. https://doi.org/10.1016/J.JCF.2019.03.001.
Orenstein DM, Franklin BA, Doershuk CF, Hellerstein HK, Germann KJ, Horowitz JG, et al. Exercise Conditioning and Cardiopulmonary Fitness in Cystic Fibrosis: The Effects of a Three-month Supervised Running Program. Chest 1981;80:392–8. https://doi.org/10.1378/CHEST.80.4.392.
Strauss GD, Osher A, Wang CI, Goodrich E, Gold F, Colman W, et al. Variable Weight Training in Cystic Fibrosis. Chest 1987;92:273–6. https://doi.org/10.1378/CHEST.92.2.273.
Simpson K, Killian K, McCartney N, Stubbing DG, Jones NL. Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation. Thorax 1992;47:70–5. https://doi.org/10.1136/THX.47.2.70.
Painter P. Exercise in chronic disease: Physiological research needed. Exerc Sport Sci Rev 2008;36:83–90. https://doi.org/10.1097/JES.0b013e318168edef.
Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The Prognostic Value of Exercise Testing in Patients with Cystic Fibrosis. New England Journal of Medicine 1992;327:1785–8. https://doi.org/10.1056/NEJM199212173272504.
Killian KJ, Jones NL. The use of exercise testing and other methods in the investigation of dyspnea. Clin Chest Med 1984;5:99–108. https://doi.org/10.1016/s0272-5231(21)00235-5.
Cerny FJ, Pullano TP, Cropp GJA. Cardiorespiratory adaptations to exercise in cystic fibrosis. Am Rev Respir Dis 1982;126:217–20. https://doi.org/10.1164/ARRD.1982.126.2.217.
Jarad NA, Giles K. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. 2008;5:29–33. https://doi.org/10.1177/1479972307085635.
Burtin C, Van Remoortel H, Vrijsen B, Langer D, Colpaert K, Gosselink R, et al. Impact of exacerbations of cystic fibrosis on muscle strength. Respir Res 2013;14. https://doi.org/10.1186/1465-9921-14-46.
Savi D, Simmonds N, Di Paolo M, Quattrucci S, Palange P, Banya W, et al. Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis. BMC Pulm Med 2015;15. https://doi.org/10.1186/S12890-015-0151-7.
Zach MS, Purrer B, Oberwaldner B. EFFECT OF SWIMMING ON FORCED EXPIRATION AND SPUTUM CLEARANCE IN CYSTIC FIBROSIS. The Lancet 1981;318:1201–3. https://doi.org/10.1016/S0140-6736(81)91440-9.
Troosters T, Langer D, Vrijsen B, Segers J, Wouters K, Janssens W, et al. Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. European Respiratory Journal 2009;33:99–106. https://doi.org/10.1183/09031936.00091607.
Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The Prognostic Value of Exercise Testing in Patients with Cystic Fibrosis. New England Journal of Medicine 1992;327:1785–8. https://doi.org/10.1056/NEJM199212173272504/ASSET/8446797E-810C-4FE2-A5ED-B8D45A2F70E4/ASSETS/IMAGES/LARGE/NEJM199212173272504_T3.JPG.
Orenstein DM, Franklin BA, Doershuk CF, Hellerstein HK, Germann KJ, Horowitz JG, et al. Exercise Conditioning and Cardiopulmonary Fitness in Cystic Fibrosis: The Effects of a Three-month Supervised Running Program. Chest 1981;80:392–8. https://doi.org/10.1378/CHEST.80.4.392.
Troosters T, Langer D, Vrijsen B, Segers J, Wouters K, Janssens W, et al. Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. European Respiratory Journal 2009;33:99–106. https://doi.org/10.1183/09031936.00091607.
Selvadurai HC, Blimkie CJ, Cooper PJ, Mellis CM, Van Asperen PP. Gender differences in habitual activity in children with cystic fibrosis. Arch Dis Child 2004;89:928–33. https://doi.org/10.1136/ADC.2003.034249.
Schneiderman-Walker J, Wilkes DL, Strug L, Lands LC, Pollock SL, Selvadurai HC, et al. Sex Differences in Habitual Physical Activity and Lung Function Decline in Children with Cystic Fibrosis. J Pediatr 2005;147:321–6. https://doi.org/10.1016/J.JPEDS.2005.03.043.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Julia Sieniawska, Angelika Kamizela, Magda Madoń, Patrycja Proszowska, Daria Sieniawska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 142
Number of citations: 0
